Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433767 | 0.74 | AGTR2 (0.56) | AGTR2AGTR1 | |
| SCHEMBL421422 | 0.74 | AGTR2 (0.56) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL23780714 | 0.74 | AGTR2 (0.55) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL23780713 | 0.74 | AGTR2 (0.55) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL29394365 | 0.70 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL8964136 | 0.70 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL244657 | 0.70 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL421411 | 0.70 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL10073578 | 0.69 | AGTR2 (0.81) | AGTR2AGTR1 | |
| SCHEMBL21602377 | 0.69 | AGTR2 (0.52) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595960-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | Spinifex Pharmaceuticals Pty Ltd (AU) | 2013-05-29 | — | — | EP | claimed |
| WO-2012010843-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2012-01-26 | — | — | WO | claimed |
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9227968-B2 | Method of treatment or prophylaxis of inflammatory pain | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-20140142116-A1 | Method of Treatment or Prophylaxis of Inflammatory Pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-05-22 | — | — | US | disclosed |
| US-8551950-B2 | Method of treatment or prophylaxis of inflammatory pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-10-08 | — | — | US | disclosed |
| US-20100292159-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN | UNIVERSITY OF QUEENSLAND (AU) | 2010-11-18 | — | — | US | disclosed |
| EP-1996183-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFLAMMATORY PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007106938-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFLAMMATORY PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-09-27 | — | — | WO | disclosed |
| US-5246943-A | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties | WARNER-LAMBERT COMPANY (US) | 1993-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885AGTR1 2/4885 |
| US-20140142116-A1 | Method of Treatment or Prophylaxis of Inflammatory Pain | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885AGTR1 2/4885 |
| US-20100292159-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.